News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,439 Results
Type
Article (39634)
Company Profile (247)
Press Release (657558)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204133)
Career Advice (2007)
Deals (35416)
Drug Delivery (95)
Drug Development (81035)
Employer Resources (172)
FDA (16171)
Job Trends (14851)
News (345131)
Policy (32526)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2553)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49404)
ALS (86)
Alzheimer's disease (1369)
Antibody-drug conjugate (ADC) (112)
Approvals (16174)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (15)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (62)
Brain cancer (26)
Breast cancer (265)
Cancer (2094)
Cardiovascular disease (167)
Career advice (1674)
Career pathing (29)
CAR-T (143)
Cell therapy (404)
Cervical cancer (19)
Clinical research (65846)
Collaboration (796)
Compensation (514)
Complete response letters (19)
COVID-19 (2582)
CRISPR (37)
C-suite (223)
Cystic fibrosis (100)
Data (2055)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (258)
Diagnostics (6348)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86340)
Editorial (35)
Employer branding (21)
Employer resources (146)
Events (111929)
Executive appointments (695)
FDA (17364)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (718)
Gene editing (100)
Generative AI (19)
Gene therapy (285)
GLP-1 (699)
Government (4408)
Grass and pollen (4)
Guidances (51)
Healthcare (18812)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (110)
Indications (27)
Infectious disease (2722)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (311)
IPO (16495)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (36)
Layoffs (461)
Leadership (16)
Legal (7906)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (283)
MASH (62)
Medical device (13349)
Medtech (13354)
Mergers & acquisitions (19439)
Metabolic disorders (658)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (83)
Neuropsychiatric disorders (24)
Neuroscience (1874)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2540)
Now hiring (38)
Obesity (354)
Opinion (204)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (146)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (46)
People (57215)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20506)
Phase II (28991)
Phase III (21613)
Pipeline (1115)
Policy (130)
Postmarket research (2563)
Preclinical (8677)
Press Release (64)
Prostate cancer (99)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (372)
Real estate (5906)
Recruiting (65)
Regulatory (22208)
Reports (46)
Research institute (2319)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2183)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (26)
The Weekly (28)
United States (22049)
Vaccines (669)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Today (79)
Last 7 days (431)
Last 30 days (2223)
Last 365 days (32874)
2025 (9282)
2024 (35219)
2023 (40080)
2022 (51182)
2021 (55725)
2020 (54085)
2019 (46541)
2018 (35022)
2017 (32109)
2016 (31483)
2015 (37552)
2014 (31321)
2013 (26349)
2012 (28570)
2011 (29264)
2010 (27330)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37776)
Australia (6177)
California (5793)
Canada (1943)
China (493)
Colorado (254)
Connecticut (262)
Delaware (136)
Europe (81027)
Florida (862)
Georgia (202)
Idaho (57)
Illinois (513)
India (25)
Indiana (301)
Iowa (10)
Japan (150)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (858)
Massachusetts (4335)
Michigan (215)
Minnesota (379)
Mississippi (2)
Missouri (79)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1665)
New Mexico (28)
New York (1659)
North Carolina (937)
North Dakota (7)
Northern California (2540)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1305)
Puerto Rico (11)
Rhode Island (31)
South America (1096)
South Carolina (20)
South Dakota (1)
Southern California (2183)
Tennessee (99)
Texas (861)
Utah (172)
Virginia (136)
Washington D.C. (59)
Washington State (530)
West Virginia (3)
Wisconsin (51)
697,439 Results for "anges inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).
January 18, 2024
·
6 min read
Press Releases
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
December 4, 2024
·
3 min read
Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy
Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats.
October 5, 2023
·
3 min read
Drug Development
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study.
November 14, 2023
·
3 min read
BioCapital
Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
Innovent Biologics, Inc. presents latest data of two ophthalmic bispecific antibodies at the American Academy of Ophthalmology 2023 Annual Meeting, including a Phase 2 clinical study of anti-VEGF and anti-complement bispecific fusion protein for neovascular age-related macular degeneration and a Phase 1 clinical study of anti-VEGF-A/Ang-2 bispecific antibody for diabetic macular edema.
November 5, 2023
·
7 min read
Drug Development
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).
May 23, 2023
·
7 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
Press Releases
FDA Classifies Q’Apel Medical Inc.'s Worldwide Medical Device Recall and Discontinuation of its 072 Aspiration System (Hippo) as Class I
April 18, 2025
·
4 min read
Press Releases
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
April 14, 2025
·
9 min read
1 of 69,744
Next
